The Branched Graft Tracker: A ground-breaking surgical device for Aortic Aneurysm treatment
| Reference number | |
| Coordinator | Endovascular Development AB |
| Funding from Vinnova | SEK 2 500 000 |
| Project duration | June 2012 - December 2014 |
| Status | Completed |
Important results from the project
The end result of this Forska och väx project was that Endovab should develop and CE mark a new med tech product. Today the development of the product is finialised and only some of the final testing remains.
Expected long term effects
With the new LGF treatment method of complicated aortic aneurysm the following benefits could be achieved: reduce mortality, reduced need for postoperative IC, reduced time between diagnosis and treatment, more patients would be allowed treatments and the combinations of these benefits would have a positive effect on health economics.
Approach and implementation
The project has achieved most of the milestones defined in the initial Vinnova application. During the last 18 month the LGF product has undergone multiple studies, achieved proof of concept and thereby reduced the main project- and product-risks considerably.